Technology | Computed Tomography (CT) | September 09, 2015

FDA Clears Philips Spectral CT Diagnostic Suite

On-demand visualization and analytics solution for Philips IQon Spectral CT delivers expanded clinical applications

 

spectral CT, Philips, IQon

Radiologists using the Philips spectral CT software to view a spectral CT image reconstruction at various energy levels.


September 9, 2015 — The U.S. Food and Drug Administration (FDA) granted 510(k) for Philips Healthcare’s Spectral Diagnostic Suite (SpDS), which offers a set of advanced visualization and analysis tools designed for the IQon Spectral computed tomography (CT) technology. The software offers enhanced spectral viewing and clinical applications capabilities.

 
CT imaging is widely used in the diagnosis of many different diseases and injuries. By providing spectral capabilities within traditional CT applications, SpDS offers a new level of flexibility for CT users. It allows clinicians to utilize the spectral information on-demand, without the added complexity of special modes or workstations that disrupt user workflow. Additionally, because there is no need to bring the patient back for additional imaging, on-demand spectral analysis of a particular region allows the physician to further analyze incidental findings.   
"Philips Spectral suite offers a new level of control for clinicians, allowing for segmentation on different energy levels, more detailed comparison between images, and advanced fusion capabilities, for diagnostic confidence,” said Prabhakar Rajiah, MBBS, M.D., FRCR, assistant professor of radiology, University Hospitals of Cleveland, UH Case Medical Center, Department of Radiology, who collaborated with Philips on the development of the suite. 

The Philips SpDS package includes:
·      Spectral enhanced Comprehensive Cardiac Analysis (sCCA)
·      Spectral enhanced Advanced Vessel Analysis (sAVA)
·      Spectral enhanced Tumor Tracking (sTT).
 
The Philips SpDS also allows for viewing and analysis of spectral datasets in a variety of settings: a reading room, on picture archiving and communication systems (PACS), or from remote locations.

Spectral CT imaging allows viewing of the same anatomy at two different kV energies. Different anatomical features are enhanced and easier to see at different energy levels. Additionally, the spectral software can highlight or eliminate specific chemical compounds based on their atomic number, including iodine, calcium, etc. This allows differentiation between calcified coronary lesions and iodine contrast in the blood vessel, or enables contrast and non-contrast images from the same scan.
 
For more information: www.spectralctlearningcenter.philips.com


Additional Content

News | Cardiac Imaging

Nov. 2, 2026 – Conavi Medical Corp. has announced the completion of the first U.S. placement and clinical cases with ...

Home November 03, 2026
Home
News | Cardiac Imaging

Oct. 6, 2026 — Riverain Technologies has announced that its FDA-cleared ClearRead Chest suite will be available through ...

Home October 08, 2026
Home
News | Cardiac Imaging

Aug. 12, 2026 — Salus Scientific has launched its Clinical Insights Series, a new publication platform designed to share ...

Home August 17, 2026
Home
News | Cardiac Imaging

Aug. 12, 2026 — Ventripoint Diagnostics is expanding subscription-based access to its VMS+ 4.0, its FDA-cleared platform ...

Home August 14, 2026
Home
News | Cardiac Imaging

August 4, 2026 - Epsilon Imaging and ASCEND Cardiovascular have announced a strategic non-exclusive partnership designed ...

Home August 13, 2026
Home
Subscribe Now